Parkinson's Disease (PD) is a common neurodegenerative disorder, more common in middle-aged and elderly people. The cause is unclear and may be related to genetic, environmental factors and the aging of the nervous system.

Recently, six companies in the field of cell and gene therapy (CGT) in China have completed a new round of financing. Among them, Eashare Biotech's Series B financing of 235 million yuan is the highest, followed by Rejuve Therapeutics' Series B+ financing

The "China Parkinson's Disease Report 2025" was officially released.

Mesenchymal stem cells (MSCs) are pluripotent stem cells derived from mesoderm, which are widely found in bone marrow, umbilical cord, adipose tissue, placenta and other tissues.

NMPA issued the Implementation Measures for Drug Trial Data Protection (Trial, Draft for Comments) and the Working Procedures for Drug Trial Data Protection (Draft for Comments).

Recently, Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration and the Medical Drugs Administration jointly issued the "Biomedical New Technology Transformation and Application Implementation Catalog (Second batch)".

This paper comprehensively reviewed and analyzed the clinical trial progress of hPSC therapy in the world up to December 2024, providing an important reference for understanding the research status, challenges and future development direction in this field

On the evening of February 19, a document titled "Opinions on Improving the Drug Price Formation Mechanism (Draft for Comments)" was circulated in the industry.